ProCE Banner Activity

乙型肝炎咨询:美国、欧洲和亚太地区指南 关于是否治疗以及如何治疗 HBV 的建议

Tool

使用此互动式决策支持工具了解基于指南的患者特定 HBV 管理建议。

 

启动此工具需要 CCO 帐户。要创建免费 CCO 帐户,请单击此处。

Released: September 27, 2019

Expiration: September 25, 2020

No longer available for credit.

Share

Faculty

Kosh Agarwal

Kosh Agarwal, MD

Consultant Hepatologist and Transplant Physician
Institute of Liver Studies
Kings College Hospital NHS Foundation Trust
London, United Kingdom

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Grace LH Wong

Grace LH Wong, MD

Professor
Gastroenterology and Hepatology
Assistant Dean (Learning Experience)
Director
CUHK Medical Data Analytics Centre (MDAC)
Faculty of Medicine
The Chinese University of Hong Kong
Hong Kong, China

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Gilead Text

Partners

AHF

ProCE Banner

ALF

ProCE Banner

Target Audience

本计划适用于为 HBV 感染患者提供医疗诊治的医生和其他医疗保健提供者。

Learning Objectives

Upon completion of this activity, participants should be able to:

  • 确定每位慢性 HBV 感染患者目前是否是治疗候选者
  • 适当监测未接受治疗的 HBV 患者,以确保及时发现其病情变化,从而使治疗变得合理
  • 以临床实践指南为指导,针对患者个体情况选择合适的治疗方案

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Kosh Agarwal, MD

Consultant Hepatologist and Transplant Physician
Institute of Liver Studies
Kings College Hospital NHS Foundation Trust
London, United Kingdom

Kosh Agarwal, MD 披露,他收到过吉利德科学公司和默沙东&公司的研究支持基金以及 Arbutus、吉利德科学和 Vir Biotechnology 公司的咨询费。

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Paul Y. Kwo, MD 披露,他收到过 Assembly、百时美施贵宝和吉利德科学公司的研究支持基金;曾担任艾伯维、Arrowhead、百时美施贵宝、吉利德科学和 Quest 公司的顾问委员会成员;并曾担任强生公司的数据和安全监控委员会&成员。

Grace LH Wong, MD

Professor
Gastroenterology and Hepatology
Assistant Dean (Learning Experience)
Director
CUHK Medical Data Analytics Centre (MDAC)
Faculty of Medicine
The Chinese University of Hong Kong
Hong Kong, China

Grace LH Wong, MD: consultant/advisor/speaker: Abbott, AbbVie, Bristol Myers Squibb, Echosens & Furui, Gilead, GlaxoSmithKline, Janssen, Roche; researcher: Gilead.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD 没有需要报告的真正或明显的利益冲突。

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA 没有需要报告的真正或明显的利益冲突。

Anna Poppa,

Managing Editor, HIV
Clinical Care Options, LLC

Anna Poppa 没有需要报告的真正或明显的利益冲突。

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD 没有需要报告的真正或明显的利益冲突。

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc 没有需要报告的真正或明显的利益冲突。

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

 

Goal


本活动的目的是提高参与者识别 HBV 治疗候选者以及监测和管理 HBV 感染者的能力。